Natalizumab cuts work absenteeism in patients with MS: real-world data
An Australian analysis shows the selective immunosuppressant has superior effects for several patient-reported outcomes
Natalizumab therapy is linked to several better health and work outcomes compared with other disease-modifying drug therapies in patients with MS, according to real-world data.
Overall, use of the monoclonal antibody was associated with superior effects over time in eight out of 23 outcome parameters, including balance, bladder symptoms and allowing patients to keep working, researchers say.
